<DOC>
	<DOCNO>NCT00925743</DOCNO>
	<brief_summary>This study design phase 1 , multicenter , open-label , single arm , dose-escalation , study Cabazitaxel combination cisplatin , determine safety , pharmacokinetics ( PK ) , efficacy solid tumor ( part 1 2 ) single sequence , two-treatment , crossover study determine effect strong CYP3A4 inhibition induction PK Cabazitaxel patient solid tumor ( part 3 part 4 , respectively ) . There 4 part study : Part 1 : Determine Dose Limiting Toxicities ( DLT ) 's Maximum Tolerated Dose ( MTD ) base safety . Part 2 : Determine anti-tumor activity combination regimen Maximum Tolerated Dose ( MTD ) extend cohort patient . Part 3 : Determine effect strong CYP3A4 inhibitor ( ketoconazole ) pharmacokinetic ( PK ) Cabazitaxel . Part 4 : Determine effect strong CYP3A4 inducer ( rifampin ) pharmacokinetic ( PK ) Cabazitaxel .</brief_summary>
	<brief_title>A Study Evaluate Effects Combining Cabazitaxel With Cisplatin Given Every 3 Weeks Patients With Advanced Solid Cancer</brief_title>
	<detailed_description>The total duration study per subject 26 week broken follow : - A maximum 21-day screening phase , - 21-days ( +/- 2 week ) study treatment cycle , - 30-day follow-up visit last dose study medication . - Cut-off date part 1 , 2 , 3 4 : last patient complete 6 cycle ( part 1 2 ) 2 cycle ( part 3 4 ) treatment discontinue study treatment ( disease progression , unacceptable toxicity , withdrawal consent , investigator 's decision withdraw ) , whichever come first , correspond part . Patients still receive treatment cut-off date may continue receive treatment beyond cut-off date investigator 's discretion benefiting .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : confirm metastatic unremovable advanced solid malignancy metastatic unresectable , standard curative measure exist , cisplatin base therapy appropriate sign informed consent Exclusion criterion limit physical functioning ( evaluated Eastern Cooperative Oncology Group ( ECOG ) scale ) inability follow study requirement schedule treatment cancer within 3 week study , concurrent treatment another clinical trial cancer therapy serious medical illness time study and/or significantly abnormal lab report lack pregnancy contraception ( woman childbearing potential ) , pregnancy , breast feeding . Women childbearing potential protect highly effective contraceptive method birth control OTHER hormonal contraception ( Part 4 ) . prior significant hear kidney problem continue toxic effect prior chemotherapy cancer physically measure ( Part 2 ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>XRP6258</keyword>
	<keyword>cisplatin</keyword>
	<keyword>Antineoplastic Combined Chemotherapy Protocols</keyword>
</DOC>